Pay attention to the suitability of choosing ppe

FENGYAN underwear brand , finished with foreign high-quality fabrics, designed by France, Hong Kong, a senior designer, well-known designer digestion and absorption, the product suitable for Chinese people's body characteristics. The full range of product categories, series, fashionable and chic, with the rapid market feedback, fast delivery accurate and professional service to our customers even more at ease!
Feng Yan is to lead the fashion underwear brand, in order to achieve "more women feel comfortable and stylish underwear" as its mission, and "unite forge ahead, the actual effect of innovation," the entrepreneurial spirit of unremitting efforts.

Feng Yan brand introduction

Design Style: Personality, Fashion Product Features: Comfortable, Healthy, Green Advertising Language: Pursuit of Fashion, Individuality Self-Brand Faith: Simple but Not Simple Brand Style: Simple and Shaping Personality Design Concept: Satisfying Different Women's Aesthetics to Meet Different Thoracic Types Demand Brand positioning: stylish, comfortable, elegant Price Positioning: 28-699 yuan Color Positioning: Popular color Style positioning: fashion, urban style Consumer age: 25-35 consumers: fashion, mature women Consumer income: middle income peak Yan underwear

Rimegepant Intermediates

Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] are the only members of the "gepants" family of medications remaining in development, and the only CGRP antagonists that possess oral bioavailability. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.

Rimegepant Intermediates,Rimegepant Cas 1190363-46-2,Rimegepant Cas 1373116-06-3,Rimegepant Cas 1190363-45-1

Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com